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ype B Dissections?
Report From the International Registry
f Acute Aortic Dissection*
lan B. Lumsden, FACS, Michael J. Reardon, FACS
ouston, Texas
he challenge of the acute type B dissection remains as
ormidable now as it did 28 years ago (1) when DeBakey and
rawford began to classify and intervene on this challenging
roblem. The average physician dreads the transfer of these
atients because of the unpredictability of the clinical course
nd the unforgiving nature of its complications.
In the absence of prospective randomized trials of medical
herapy versus open surgery versus stent grafting, clinicians are
uided by the best available data. The investigators of this
eport (2) and the founders of the International Registry of
cute Aortic Dissection (IRAD) are to be congratulated on
heir vision and creation of the IRAD and for providing us
ith these “best available data.” This information is currently
eing utilized to guide and power clinical trials specifically
ddressing therapy of acute type B aortic dissection.
See page 395
The weakness of IRAD consists of data collection in both
prospective and retrospective manner, absence of random-
zation, vagaries of referral patterns, lack of long-term
ollow-up; its clear strength is in the consecutive large
umbers (571 cases) and propensity scoring in this article.
hat the data was pooled from 20 aortic centers and 9
ountries further enhances the prestige of the database. The
ultidisciplinary founders of IRAD and the investigators of
his report have come to be recognized as being among the
ost knowledgeable physicians in the aortic dissection
rena and have made invaluable contributions in this field.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.3
From the Department of Cardiovascular Surgery, Methodist DeBakey Heart and
ascular Center, The Methodist Hospital Research Institute, Houston, Texas.hat Are the Therapeutic Goals
n Type B Dissection?
he goal of medical therapy is “short-term complication
voidance.” It does not resolve the dissection; indeed, under
he best-case scenario, it commits the patient to life-long
ggressive antihypertensive therapy and life-long surveil-
ance in most cases with computed tomography scanning
ith its attendant radiation and contrast exposure. Subse-
uent intervention is required in 25% to 30% of patients (3)
or aneurysm expansion, progressive dissection, and other
omplications from the unresolved dissection process.
hile in-hospital blood pressure control can often be
recisely achieved, there are little data on patient compli-
nce and no data on 24-h blood pressure control on the
utcome of dissections once the patient is in the outpatient
etting (4). Adequacy of blood pressure control at follow-up
as been reported as predictive of reintervention for type B
issections (5) and after type A repair (6). Good blood
ressure control remains the rationale for advocating con-
inued medical therapy for dissections. In the medical
herapy group, “once dissected, always dissected.” Avoid-
nce of short-term complications, life-long blood pressure
ontrol, life-long imaging and surgical intervention for up to
0% of the failures is currently the gold standard!
One of the appealing aspects of stent grafting is the
lusive paradigm of dissection healing—false lumen throm-
osis and remodeling of the aortic wall (7,8). This is a very
owerful observation and treatment goal, which raises more
uestions than it currently answers. Reapposition of the true
nd false lumen has in many cases produced complete
isappearance (at least by contemporary imaging standards)
f the dissection. This typically occurs along the length of
he stent graft, with reappearance of the dissection in our
xperience at the end or immediately proximal to the end of
he device. The dissection then persists distally. These
reliminary multiauthor observations tantalize us with the
ecognition that:
) Endovascular devices can initiate false lumen thrombosis.
) False lumen thrombosis can result in aortic wall healing.
) Absence of the device leads to reperfusion of the false
lumen in most cases.
Clearly these preliminary observations raise the concept
hat bare stents beyond the covered portion may result in
dditional wall healing. This is the premise of the TX-2 trial
urrently underway in Europe (9). This scenario then raises
nother entire list of intriguing questions:
) Is the healed wall resistant to redissection?
) Are the presumed device-related complications suffi-
ciently low to accept this aggressive endoluminal treat-
ment strategy?) Does this reduce long-term dissection morbidity?
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404) Does this reduce or ameliorate the need for long-term
antihypertensive control and imaging follow-up?
These are tantalizing questions that beg analytical and
uantitative answers, which currently do not exist. In the
bdominal aortic aneurysm environment, sac shrinkage and,
n some cases, complete resolution is observed, but does not
ppear to result in sac healing and fibrosis. Consequently,
tabilization of the aortic wall in the absence of stent graft
ntegrity does not develop, rapid re-expansion occurs if repres-
urization occurs. A contemporary report from Beijing (10) in
3 patients treated with stent grafts for type B dissection
eported a 3.2% mortality rate and complete thrombosis of the
alse lumen in 98.4% at 12-month follow-up. If validated by
ther centers, this would be yet another piece of evidence that
upports the observations in this manuscript supporting the
ole for stent grafting in type B dissections.
alperfusion Drives Morbidity and Mortality
lthough in this series the morbidity for fenestration (connect-
ng true and false lumen to equilibrate pressure on each side,
hereby restoring flow to visceral vessels) was low, fenestration
oes nothing to stabilize the aneurysm, protect against future
xpansion, and, in some cases, fails to restore organ flow. In our
nstitution, “primary” fenestration has largely been abandoned
n favor of “primary stent grafting” and secondary fenestration
f the stent graft fails to restore vital organ perfusion. The
ationale for this approach is as stated by the investigators (2):
) Redirection of flow back into the true lumen by stent
grafting usually results in organ reperfusion.
) The stent graft also has a direct influence on the
dissection (stabilization, induction of thrombosis).
Although physicians agonize over identifying which lu-
en perfuses which visceral vessels, in an effort to predict the
eneficial or deleterious effects of stent grafting, in practice this
s usually irrelevant. The reason for this irrelevance is that the
ntima torn out of a renal artery orifice often returns to that
pot when the stent graft is inserted. Rarely is supplemental
enal stenting even required, but when necessary is a relatively
mall incremental procedure. We believe that this is the
eason stent grafting restored visceral perfusion in 16 of 17
atients in this study compared with 9 of 18 with fenestra-
ion and only 4 of 14 with open surgery.
ecognition and Therapy for
cute Aortic Pathologies
ecently a broad group of conditions referred to as “acute
ortic syndromes” has been defined (11). Many of these may
epresent stages in evolution of the same process: intramural
ematoma; dissection; aneurysm formation, penetrating
lcer; saccular aneurysm. Nevertheless, they all represent mife-threatening aortic pathology especially in the acute
resentation. The poster child for this acuity is the type A
ascending) aortic dissection) where mortality is measured as
% per hour. Misdiagnosis of these pathologies usually
ecause of confusion with myocardial ischemia has led to
ntimely deaths and high profile lawsuits. Because of the
uccess of national standards for expediting the care of
atients with acute myocardial infarction (door-to-balloon
ime 60 min) and acute ischemic stroke (lysis with 3 h of
vent), we believe that similar standards should be evolved
or acute aortic emergencies. With this in mind, we have
reated an Acute Aortic Treatment Center that focuses on
ublic education, education of emergency room physicians
nd cardiologists on identification of the patient with
typical chest pain (12). The rapid transportation of these
atients to an appropriate facility and the rapid triage and
nstitution of appropriate therapy of these diverse pathologies.
he establishment of an “acute aortic treatment center,” we
elieve, is the next step in furthering the goal of IRAD to
educe morbidity and mortality from acute aortic disease.
eprint requests and correspondence: Dr. Alan B. Lumsden,
epartment of Cardiovascular Surgery, 6560 Fannin Street, Suite
006, Houston, Texas 77030. E-mail ablumsden@tmhs.org.
EFERENCES
1. Crawford ES. The diagnosis and management of aortic dissection.
JAMA 1990;264:2537–41.
2. Fattori R, Tsai TT, Myrmel T, et al. Complicated acute type B
dissection: is surgery still the best option? A report from the Interna-
tional Registry of Acute Aortic Dissection. J Am Coll Cardiol Intv
2008;1:395–402.
3. Schor JS, Yerlioglu ME, Galla JD, Lansman SL, Ergin MA, Griepp
RB. Selective management of acute type B aortic dissection: long-term
follow-up. Ann Thorac Surg 1996;61:1339–41.
4. Grajek S, Cieœlin´ski A, Mitkowski P, et al. Results of long-term
medical treatment of patients with arterial hypertension complicated by
aortic dissection. J Hum Hypertens 1995;9:987–92.
5. Onitsuka S, Akashi H, Tayama K, et al. Long-term outcome and
prognostic predictors of medically treated acute type B aortic dissec-
tions. Ann Thorac Surg 2004;78:1268–73.
6. Zierer A, Voeller RK, Hill KE, Kouchoukos NT, Damiano RJ Jr.,
Moon MR. Aortic enlargement and late reoperation after repair of
acute type A aortic dissection. Ann Thorac Surg 2007;84:479–86.
7. Kahn SL, Dake MD. Stent graft management of stable, uncomplicated
type B aortic dissection. Perspect Vasc Surg Endovasc Ther 2007;19:
162–9.
8. Taylor PR, Bell RE, Reidy JF. Endovascular treatment of acute type B
aortic dissection. Acta Chir Belg 2004;104:513–8.
9. Morales JP, Greenberg RK, Morales CA, et al. Thoracic aortic lesions
treated with the Zenith TX1 and TX2 thoracic devices: intermediate
and long term outcomes. J Vasc Surg 2008;48:54–63.
0. Xu SD, Huang FJ, Yang JF, et al. Endovascular repair of acute type B
aortic dissection: early and mid-term results. J Vasc Surg 2006;43:1090–5.
1. Ahmad F, Cheshire N, Hamady M. Acute aortic syndrome: pathology
and therapeutic strategies. Postgrad Med J 2006;82:305–12.
2. Lumsden AB, Crawford DJ, Peden EK, et al. Establishing an acute
aortic treatment center. Endovascular Today 2007;Suppl:28–31.
ey Words: aortic dissection  stent graft  medical
anagement  acute aortic treatment center.
